From January through July this year, researchers in France administered the vaccine from Pfizer/BioNTech to 306 lung cancer patients, 70% of whom had recently received immunosuppressive therapies.
Patients with COVID-19 antibodies from a previous infection received only one dose of vaccine; most patients, however, received both doses, according to a paper scheduled for publication in the Journal of Thoracic Oncology.
About 10% of the patients failed to develop antibodies in response to the first two doses and received a third dose, which successfully induced antibodies in all but three individuals who also had blood disorders known to impair the effect of the vaccines.
The researchers noted that before vaccines, the death rate among lung cancer patients who developed COVID-19 was 30%. In this seven-month study, only eight patients, or 2.6% of the total, developed mild cases of COVID-19.
Because the study was small and not randomized, the investigators called for more research to confirm their findings.
SOURCE: https://bit.ly/3kEkxKH Journal of Thoracic Oncology, released November 15, 2021.
By Reuters Staff
Posted on
Previous Article
« Support for early valve replacement in severe aortic stenosis without symptoms Next Article
Time from stopping blood thinner to CABG can be safely shortened »
« Support for early valve replacement in severe aortic stenosis without symptoms Next Article
Time from stopping blood thinner to CABG can be safely shortened »
Related Articles
November 8, 2019
Less focus on quality of life in recent phase 3 trials
November 6, 2020
MRI may best CT for assessing mesothelioma tumor volume
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy